HK Stock MarketDetailed Quotes

3SBIO (01530)

Watchlist
  • 19.280
  • +0.300+1.58%
Noon Break May 22 11:58 CST
48.93BMarket Cap5.21P/E (TTM)

3SBIO (01530) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
Authorized income9.43B53.27%
Sale of biopharmaceuticals8.01B45.24%
合同开发与生产运营业务263.48M1.49%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
Authorized income9.43B53.27%
Sale of biopharmaceuticals8.01B45.24%
合同开发与生产运营业务263.48M1.49%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
United States of America9.52B53.77%
The mainland of China7.91B44.70%
Other countries / regions270.43M1.53%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More